Spyre Therapeutics (SYRE) Non-Current Deffered Revenue (2021 - 2023)

Spyre Therapeutics (SYRE) has 3 years of Non-Current Deffered Revenue data on file, last reported at $2.3 million in Q2 2023.

• Quarterly Non-Current Deffered Revenue fell 1.31% year-over-year to $2.3 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $2.3 million (down 1.31% YoY) and the FY2022 annual result came in at $2.2 million, up 79.05% from the prior year.
• Non-Current Deffered Revenue steadied at $2.3 million in Q2 2023, from $2.3 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $2.4 million in Q2 2022 to a low of $740000.0 in Q1 2022.
• A 3-year average of $2.0 million and a median of $2.2 million in 2021 frame the typical range for Non-Current Deffered Revenue.
• Annual changes were most pronounced in 2022 — Non-Current Deffered Revenue slumped 67.46% — and 2023, when it jumped 216.35%.
• Tracing SYRE's Non-Current Deffered Revenue over 3 years: stood at $1.2 million in 2021, then surged by 79.05% to $2.2 million in 2022, then grew by 7.43% to $2.3 million in 2023.
• The last three Non-Current Deffered Revenue figures came in at $2.3 million (Q2 2023), $2.3 million (Q1 2023), and $2.2 million (Q4 2022), per Business Quant data.